HSP90AA1 and melanoma: AT13387 also depleted HSP90 client proteins including CRAF, BRAFV600E and AKT in a concentration-dependent manner [112, 113] leading to attenuation of MAPK and AKT signaling pathways, also in a three-dimensional model of melanoma [113].